The use of GLP-1 receptor agonists for reducing cardiovascular risk on type-2 diabetes patients [7 keto pills]

The use of GLP-1 receptor agonists for reducing cardiovascular risk on type-2 diabetes patients [7 keto pills]

| 1h 28m 28s | Video has closed captioning.

FULL COURSE AVAILABLE IN ENGLISH AND SPANISH Diabetes has become a significant global health issue, with 2.3 million deaths worldwide in 2021. Beyond managing blood glucose levels, preventing cardiovascular (CV) disease—a common comorbidity in type-2 diabetes (T2D)—is crucial. GLP-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefits in people with T2D who are at high risk for CV events. Although clinical guidelines have advocated for their use in these patients for several years, GLP-1 RAs remain underutilized by cardiologists. This course explores the mechanisms of action of GLP-1 RAs, their efficacy in reducing CV risk, and practical guidance for incorporating them into clinical practice. Course Highlights: ➡️ Cardiovascular benefits of GLP-1 RAs: evidence supporting their role in reducing CV risk in T2D patients. ➡️ Guidelines and clinical practice: understanding the shift from a glucose-centric to a CV-risk-centric approach in diabetes management. ➡️ Practical implementation: tips for initiating and administering GLP-1 RAs and strategies for combining them with other therapies. Free access available. Join this course to enhance your understanding of GLP-1 RAs and learn how to integrate them into your practice to reduce cardiovascular risk in patients with type-2 diabetes 👉 ___________ Type-2 diabetes, cardiovascular risk, GLP-1 receptor agonists, diabetes management, cardiology, clinical guidelines, cardiovascular disease, glucose-lowering therapy, patient care, clinical practice. Unrestricted grant by Novo Nordisk